Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021

SELL
$11.2 - $27.7 $502,196 - $1.24 Million
-44,839 Closed
0 $0
Q3 2020

Oct 20, 2020

BUY
$10.6 - $16.6 $48,431 - $75,845
4,569 Added 11.35%
44,839 $56,000
Q2 2020

Jul 16, 2020

BUY
$10.3 - $17.3 $414,781 - $696,671
40,270 New
40,270 $52,000

About Cellectar Biosciences, Inc.


  • Ticker CLRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,114,290
  • Market Cap $1.59M
  • Description
  • Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...
More about CLRB
Track This Portfolio

Track Wedbush Securities Inc Portfolio

Follow Wedbush Securities Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wedbush Securities Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wedbush Securities Inc with notifications on news.